Molecular Immunohistochemical Profiling Identifies Invasive Breast Carcinoma
By LabMedica International staff writers Posted on 23 Oct 2014 |
Molecular and immunohistochemical profiling of invasive micropapillary carcinoma of the breast was used to identify potentially useful markers for targeted therapies with a focus on a specific gene mutation.
Clinical outcomes for this subtype of breast cancer, invasive micropapillary carcinoma (IMPC), have generally found it to be more aggressive with regard to histopathologic features, stage at presentation, and clinical outcomes compared with invasive carcinoma of no specific type.
Pathologists working with the Iowa Institute of Human Genetics (Iowa City, IA, USA) obtained formalin-fixed, paraffin-embedded tumor blocks from seven patients identified from the archives at their institution and tumor registry from 1997 to 2012. Each case was reviewed by two surgical pathologists and the previously documented diagnosis of IMPC was confirmed. Areas with the highest percentage of tumor were identified on the hematoxylin-eosin slide and corresponding areas from the unstained slides were manually microdissected using a razor blade.
Massively parallel (Next-generation) sequencing was performed using the Ion AmpliSeq Cancer Hotspot Panel version 2 (Life Technologies, Carlsbad, CA, USA). Mutation analysis for B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E was performed using a single nucleotide primer extension assay using the SNaPshot Multiplex kit (Applied Biosystems; Foster City, CA, USA). Immunohistochemistry studies for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her2/Neu), phosphatase and tensin homolog (PTEN), and non-metastatic protein 23 homologue 1 (NM23H1) were performed using the same tumor blocks.
The scientists found no pathogenic mutations in the tumors by next-generation sequencing. The lack of BRAF V600E mutation was confirmed by single nucleotide primer extension assay. All tumors were positive for ER and PR, and showed no overexpression of Her2/Neu. Loss of or reduced PTEN expression was observed in six of seven cases and was associated with lymph node metastasis. Reduced NM23H1 expression was observed in three of seven cases, all of which had concurrent PTEN loss.
The authors concluded that no somatic mutation could be identified consistent with the reported lack of driver mutations in this tumor. The frequent loss of PTEN in invasive micropapillary carcinoma may have implications for targeted therapy towards the phosphatidylinositol-4,5-bisphosphate 3-kinase pathway in this subgroup of patients. The study was published on October 3, 2014, in the journal Pathology and Laboratory Medicine International.
Related Links:
Iowa Institute of Human Genetics
Life Technologies
Applied Biosystems
Clinical outcomes for this subtype of breast cancer, invasive micropapillary carcinoma (IMPC), have generally found it to be more aggressive with regard to histopathologic features, stage at presentation, and clinical outcomes compared with invasive carcinoma of no specific type.
Pathologists working with the Iowa Institute of Human Genetics (Iowa City, IA, USA) obtained formalin-fixed, paraffin-embedded tumor blocks from seven patients identified from the archives at their institution and tumor registry from 1997 to 2012. Each case was reviewed by two surgical pathologists and the previously documented diagnosis of IMPC was confirmed. Areas with the highest percentage of tumor were identified on the hematoxylin-eosin slide and corresponding areas from the unstained slides were manually microdissected using a razor blade.
Massively parallel (Next-generation) sequencing was performed using the Ion AmpliSeq Cancer Hotspot Panel version 2 (Life Technologies, Carlsbad, CA, USA). Mutation analysis for B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E was performed using a single nucleotide primer extension assay using the SNaPshot Multiplex kit (Applied Biosystems; Foster City, CA, USA). Immunohistochemistry studies for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her2/Neu), phosphatase and tensin homolog (PTEN), and non-metastatic protein 23 homologue 1 (NM23H1) were performed using the same tumor blocks.
The scientists found no pathogenic mutations in the tumors by next-generation sequencing. The lack of BRAF V600E mutation was confirmed by single nucleotide primer extension assay. All tumors were positive for ER and PR, and showed no overexpression of Her2/Neu. Loss of or reduced PTEN expression was observed in six of seven cases and was associated with lymph node metastasis. Reduced NM23H1 expression was observed in three of seven cases, all of which had concurrent PTEN loss.
The authors concluded that no somatic mutation could be identified consistent with the reported lack of driver mutations in this tumor. The frequent loss of PTEN in invasive micropapillary carcinoma may have implications for targeted therapy towards the phosphatidylinositol-4,5-bisphosphate 3-kinase pathway in this subgroup of patients. The study was published on October 3, 2014, in the journal Pathology and Laboratory Medicine International.
Related Links:
Iowa Institute of Human Genetics
Life Technologies
Applied Biosystems
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Pathology News
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments